



- (51) **International Patent Classification:**
A61B 5/00 (2006.01) *G06F 19/00* (2011.01)
- (21) **International Application Number:**
PCT/SG2013/000122
- (22) **International Filing Date:**
28 March 2013 (28.03.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/618,618 30 March 2012 (30.03.2012) US
- (71) **Applicants:** **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG). **NATIONAL UNIVERSITY OF SINGAPORE** [SG/SG]; 10 Kent Ridge Crescent, Singapore 119260 (SG). **INSTITUTE OF MENTAL HEALTH** [SG/SG]; Buangkok Green Medical Park, 10 Buangkok View, Singapore 539747 (SG).
- (72) **Inventors:** **ZHANG, Haihong**; c/o PKM, Institute for Infocomm Research, 1 Fusionopolis Way, #21-01 Connexis, South Tower, Singapore 138632 (SG). **GUAN, Cuntai**; c/o PKM, Institute for Infocomm Research, 1 Fusionopolis Way, #21-01 Connexis, South Tower, Singapore 138632 (SG). **KRISHNAN, Ranga**; c/o Duke-NUS Graduate Medical School, National University of Singapore, 21 Lower Kent Ridge, Singapore 119077 (SG). **LEE, Tih-Shih**; c/o Duke-NUS Graduate Medical School, National University of Singapore, 21 Lower Kent Ridge, Singapore 119077 (SG). **LIM, Choon Guan**; c/o Institute of Mental

Health, Buangkok Green, Medical Park, 10 Buangkok View, Singapore 539747 (SG). **FUNG, Daniel**; c/o Institute of Mental Health, Buangkok Green, Medical Park, 10 Buangkok View, Singapore 539747 (SG).

- (74) **Agent:** **SPRUSON & FERGUSON (ASIA) PTE LTD**; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG).


- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

- (54) **Title:** METHOD FOR ASSESSING THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER



- (57) **Abstract:** According to one aspect, there is provided a method for assessing the treatment of attention-deficit/hyperactivity disorder (ADHD) in a subject, the method comprising: obtaining electroencephalographic (EEG) data relating to a plurality of subjects diagnosed with ADHD; extracting, for each of the plurality of subjects, at least one feature from the EEG data relating to that subject; formulating a prediction model by performing regression analysis to map the extracted features against one or more markers for each of the plurality of subjects; and determining that the prediction model provides an ADHD assessment if one or more of the markers are indicators of a clinical measure of interest.